Recent News

---

Minimal Change Disease After Covid Vaccine: A Case Report and Implications

Summary

A new report details the case of a 19-year-old male who developed Minimal Change Disease (MCD) following his second dose of the Covishield COVID-19 vaccine. Despite no adverse reactions after the first dose, the patient experienced symptoms such as fever, edema, and decreased urine output, but successfully achieved full remission after treatment with corticosteroids.

Case Summary: Minimal Change Disease Linked to Covishield Vaccine

This case raises important questions about the potential link between Minimal Change Disease and COVID-19 vaccines, particularly adenovirus vector vaccines like Covishield. The patient developed symptoms of MCD three days after receiving his second dose of the vaccine, starting with a fever. A week later, additional symptoms emerged, including edema, frothy urine, and oliguria (decreased urine output)..

Diagnostic Findings

Diagnostic tests revealed significant markers of kidney dysfunction:

• 24-hour urine protein: 3.7 g (indicating proteinuria, a hallmark of MCD)
• Serum creatinine: 1.9 mg/dL (showing impaired kidney function)
• Serum albumin: 1.9 g/dL (indicating hypoalbuminemia)

A kidney biopsy confirmed the diagnosis of Minimal Change Disease, characterized by damage to the kidney’s podocytes—specialized cells in the glomerulus responsible for filtering blood.

Treatment and Outcomes

The patient was treated with corticosteroids, the standard therapy for Minimal Change Disease treatment, and achieved complete remission after 33 days. His kidney function improved, with significant reductions in proteinuria and the resolution of other symptoms. This case demonstrates that while MCD can develop post-vaccination, it is highly responsive to conventional treatments.

Link Between COVID-19 Vaccines and Minimal Change Disease

While the exact cause of Minimal Change Disease remains unclear, this case adds to a growing body of evidence suggesting a potential link between COVID-19 vaccination and Minimal Change Disease onset. Cases have been reported following both mRNA vaccines (such as Pfizer- BioNTech and Moderna) and adenovirus vector vaccines (such as Covishield and AstraZeneca).
In this case, the temporal relationship between vaccination and the onset of MCD symptoms, along with the exclusion of other potential causes, points to the vaccine as a possible trigger. However, the patient’s experience after the first dose of the vaccine, which was uneventful, underscores that adverse reactions may occur later, even after prior tolerance to vaccination.

Implications for Clinicians and Patients

Clinicians should be aware of the possibility of Minimal Change Disease following COVID-19 vaccination, even in individuals who did not experience any adverse effects after the first dose. Early recognition of symptoms such as edema, proteinuria, and oliguria can lead to prompt diagnosis and treatment, which is crucial for preventing kidney damage and ensuring a favorable prognosis.
As COVID-19 vaccines continue to be administered globally, it is important to document and analyze such cases to better understand the relationship between COVID-19 vaccines and rare conditions like Minimal Change Disease. Further studies are necessary to establish whether this is a direct effect of the vaccine or a rare coincidence.

Conclusion

This case report highlights the potential for Minimal Change Disease after COVID-19 vaccination, specifically after the second dose of the Covishield vaccine. While the occurrence of MCD is rare, this report emphasizes the need for vigilance among healthcare providers and patients. If diagnosed early, MCD can be effectively treated with corticosteroids, leading to a complete remission, as demonstrated by this case.

Source Link